Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.

Oncotarget - 31 Jan 2017

Levine Arnold J

Abstract excerpt

Both normal and cancerous cells, treated with drugs that block cytosine methylation of DNA, are preferentially killed by these drugs when they have p53 mutations and survive if they have a wild type protein. It appears that the wild type p53 protein functions to eliminate cells that undergo large epigenetic alterations and save other cells from death by this drug treatment. This has now been observed in cancerous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytosine

Share to Decitabine

Share to DNA, Neoplasm

Share to Drug Resistance, Neoplasm

Share to Epigenesis, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28129641
DOI: 10.18632/oncotarget.14805
PMCID: PMC5352316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.PMID 28129641Read ↗

Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.Semantic proximity Read ↗

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.Semantic proximity Read ↗

Mutant p53 rescue and modulation of p53 redox state.Semantic proximity Read ↗

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.Semantic proximity Read ↗

Novel cancer therapy by reactivation of the p53 apoptosis pathway.Semantic proximity Read ↗

Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapySemantic proximity Read ↗

The cell death machinery governed by the p53 tumor suppressor in response to DNA damageSemantic proximity Read ↗

Mutant p53 targeting by the low molecular weight compound STIMA-1.Semantic proximity Read ↗

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.Semantic proximity Read ↗

P53: an ubiquitous target of anticancer drugs.Semantic proximity Read ↗

Small molecule compounds targeting the p53 pathway: are we finally making progress?Semantic proximity Read ↗

Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.